Beta Bionics (NASDAQ:BBNX) Given New $20.00 Price Target at Stifel Nicolaus

Beta Bionics (NASDAQ:BBNX) had its target price decreased by Stifel Nicolaus from $22.00 to $20.00 in a report issued on Wednesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other brokerages also recently issued reports on BBNX. Robert W. Baird lowered their price target on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. TD Cowen started coverage on shares of Beta Bionics in a research note on Monday, January 26th. They set a “hold” rating and a $17.00 price objective for the company. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Truist Financial lowered their target price on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Finally, UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX opened at $12.20 on Wednesday. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The stock has a market cap of $543.63 million, a PE ratio of -8.08 and a beta of 5.06. The stock has a fifty day moving average of $11.55 and a 200-day moving average of $19.92.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 22.55% and a negative net margin of 60.27%.The business had revenue of $27.63 million for the quarter. On average, sell-side analysts predict that Beta Bionics will post -1.96 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC raised its stake in Beta Bionics by 0.8% in the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after purchasing an additional 37,476 shares in the last quarter. Farallon Capital Management LLC grew its stake in Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after buying an additional 110,000 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in shares of Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after buying an additional 1,509,217 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Beta Bionics during the 4th quarter valued at $40,437,000.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Raised FY‑2026 revenue guidance to $131M–$136M and increased gross‑margin outlook to 57.5%–59.5%, signaling stronger unit economics and margin expansion ahead. Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5%
• Positive Sentiment: Q1 showed strong sales growth (≈57% year‑over‑year reported in company commentary) and an EPS beat: reported loss of $0.49 vs. consensus ‑$0.53, highlighting improving operational leverage. Beta Bionics Inc (BBNX) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational …
• Neutral Sentiment: Company released the full Q1 earnings presentation and earnings‑call transcript — useful for investors assessing cadence of product adoption and margin drivers. Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Two sell‑side firms lowered price targets (Leerink: $25→$24; Stifel: $22→$20) but retained Outperform/Buy ratings — indicates continued analyst confidence but a pull‑back in near‑term valuation expectations. Benzinga coverage of analyst price target changes
• Negative Sentiment: Zacks flagged a revenue miss headline despite the EPS beat (company reported $27.63M for Q1), which may fuel short‑term selling and skepticism about top‑line momentum. Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.